Q-omics provides the consensus-scored INSL5 profile across patient tissues and cancer cell-line models. INSL5 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, INSL5 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, INSL5 RNA expression shows 10,553 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where INSL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INSL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INSL5 survival associations across molecular data types. INSL5 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INSL5 RNA expression–survival associations across cancer types. High INSL5 expression shows unfavorable associations in KICH, LGG and KIRC, but favorable associations in PAAD, ACC and CESC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for INSL5 RNA expression.
This table summarizes INSL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for INSL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INSL5 shows lower tumor expression in COAD, LUSC, READ, KICH and THCA and higher tumor expression in STAD. The COAD box plot shows higher INSL5 RNA expression in normal versus tumor tissue (log2 FC = −3.777, t-test p < 0.001).
This table shows molecular features associated with INSL5 in patient tissues and cancer cell lines. In patient samples, INSL5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, INSL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
